title: Integrating ADNI results into Alzheimer's disease drug development programs.
abstract: The Alzheimer's Disease Neuroimaging Initiative (ADNI) is providing critical new information on biomarkers in cognitively normal elderly, persons with mild cognitive impairment (MCI), and patients with mild Alzheimer's disease (AD). The data provide insights into the progression of the pathology of AD over time, assist in understanding which biomarkers might be most useful in clinical trials, and facilitate development of disease-modifying treatments. ADNI results are intended to support new AD treatment development; this report considers how ADNI information can be integrated in AD drug development programs. Cerebrospinal fluid (CSF) amyloid beta protein (Abeta) measures can be used in Phase I studies to detect any short term effects on Abeta levels in the CSF. Phase II studies may benefit most from biomarker measures that can inform decisions about Phase III. CSF Abeta levels, CSF total tau and phospho-tau measures, fluorodeoxyglucose positron emission tomography (FDG PET), Pittsburgh Compound B (PIB) amyloid imaging, or magnetic resonance imaging (MRI) may be employed to select patients in enriched trials or as outcomes for specific disease-modifying interventions. Use of biomarkers may allow Phase II trials to be conducted more efficiently with smaller populations of patients or shorted treatment times. New drug applications (NDAs) may include biomarker outcomes of phase III trials. ADNI patients are highly educated and are nearly all of Caucasian ethnicity limiting the generalizability of the results to other populations commonly included in global clinical trials. ADNI has inspired or collaborates with biomarker investigations worldwide and together these studies will provide biomarker information that can reduce development times and costs, improve drug safety, optimize drug efficacy, and bring new treatments to patients with or at risk for AD.
authors.affiliation: Mary S. Easton Center for Alzheimer's Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7226, United States. jcummings@mednet.ucla.edu
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Cummings
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000175:diagnosis* / Q000188:drug therapy*; D000818:Animals; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002986:Clinical Trials as Topic / Q000639:trends; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000639:trends; D049268:Positron-Emission Tomography / Q000639:trends
chemical_list: D015415:Biomarkers
references.citation: Neuroimage. 2008 Nov 15;43(3):458-69
references.pmid: 18691658
references.citation: J Neurosci. 2007 Oct 10;27(41):10957-68
references.pmid: 17928437
references.citation: Arch Neurol. 1999 Mar;56(3):303-8
references.pmid: 10190820
references.citation: Neurology. 2009 Dec 15;73(24):2061-70
references.pmid: 19923550
references.citation: Alzheimers Dement. 2008 Jul;4(4):255-64
references.pmid: 18631976
references.citation: Arch Neurol. 2009 Mar;66(3):382-9
references.pmid: 19273758
references.citation: Arch Neurol. 2006 May;63(5):674-81
references.pmid: 16682537
references.citation: Radiology. 2009 Apr;251(1):195-205
references.pmid: 19201945
references.citation: AAPS J. 2007 Mar 23;9(1):E105-8
references.pmid: 17408233
references.citation: Adv Exp Med Biol. 2009;655:1-12
references.pmid: 20047030
references.citation: Neurology. 2005 May 10;64(9):1553-62
references.pmid: 15883316
references.citation: Neurology. 2005 May 10;64(9):1563-72
references.pmid: 15883317
references.citation: Hippocampus. 2009 Jun;19(6):579-87
references.pmid: 19437497
references.citation: Neuroimage. 2008 Aug 1;42(1):19-27
references.pmid: 18547819
references.citation: J Alzheimers Dis. 2009;16(2):235-70
references.pmid: 19221415
references.citation: NeuroRx. 2004 Apr;1(2):189-95
references.pmid: 15717019
references.citation: J Am Geriatr Soc. 2008 Aug;56(8):1424-33
references.pmid: 18662209
references.citation: Lancet Neurol. 2008 Sep;7(9):779-86
references.pmid: 18672400
references.citation: Brain. 2008 Jun;131(Pt 6):1630-45
references.pmid: 18339640
references.citation: Toxicology. 2008 Mar 20;245(3):219-23
references.pmid: 18280028
references.citation: Science. 2009 Oct 16;326(5951):386-9
references.pmid: 19833956
references.citation: Lancet Neurol. 2007 Aug;6(8):734-46
references.pmid: 17616482
references.citation: J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):429-38
references.pmid: 16306154
references.citation: Ann Neurol. 2009 Apr;65(4):403-13
references.pmid: 19296504
references.citation: Dement Geriatr Cogn Disord. 2006;22(4):312-9
references.pmid: 16940725
references.citation: Neurology. 2010 Jan 19;74(3):201-9
references.pmid: 20042704
references.citation: Neuroscience. 2000;95(3):721-5
references.pmid: 10670438
references.citation: Brain. 2009 Aug;132(Pt 8):2036-47
references.pmid: 19439419
references.citation: Eur Radiol. 2010 Mar;20(3):674-82
references.pmid: 19760240
references.citation: J Nucl Med. 2009 Nov;50(11):1887-94
references.pmid: 19837759
references.citation: Alzheimers Dement. 2010 Jan;6(1):39-53
references.pmid: 19592311
references.citation: Alzheimers Dement. 2009 Sep;5(5):406-18
references.pmid: 19751920
references.citation: Clin Neuropharmacol. 2007 Nov-Dec;30(6):317-25
references.pmid: 18090456
references.citation: Arch Neurol. 2008 Aug;65(8):1031-8
references.pmid: 18695053
references.citation: Neurology. 2007 Oct 16;69(16):1622-34
references.pmid: 17938373
references.citation: Magn Reson Med. 2009 Aug;62(2):365-72
references.pmid: 19526493
references.citation: Neuroimage. 2009 Oct 1;47(4):1506-13
references.pmid: 19477282
references.citation: Neuroimage. 2009 Feb 15;44(4):1415-22
references.pmid: 19027862
references.citation: Annu Rev Pharmacol Toxicol. 2008;48:631-51
references.pmid: 17937595
references.citation: Exp Gerontol. 2009 Sep;44(9):579-85
references.pmid: 19539742
references.citation: Neurology. 2009 Oct 13;73(15):1193-9
references.pmid: 19822868
references.citation: N Engl J Med. 2009 Feb 19;360(8):816-23
references.pmid: 19228627
references.citation: Ann N Y Acad Sci. 2009 Oct;1180:36-46
references.pmid: 19906259
references.citation: Clin Neuropharmacol. 2010 Mar-Apr;33(2):74-8
references.pmid: 19935404
references.citation: Brain. 2009 May;132(Pt 5):1355-65
references.pmid: 19339253
references.citation: Neuroimage. 2009 Mar;45(1 Suppl):S3-15
references.pmid: 19041724
references.citation: J Neurol. 2009 Aug;256(8):1288-95
references.pmid: 19353221
references.citation: Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S15-20
references.pmid: 18631992
references.citation: Neuroimage. 2008 May 15;41(1):19-34
references.pmid: 18378167
references.citation: Neuroimage. 2009 May 1;45(4):1107-16
references.pmid: 19349228
references.citation: Neurobiol Aging. 2011 Jul;32(7):1207-18
references.pmid: 19660834
references.citation: Alzheimers Dement. 2009 Mar;5(2):108-13
references.pmid: 19328437
references.citation: Arch Neurol. 2001 Dec;58(12):1985-92
references.pmid: 11735772
references.citation: J Neurochem. 2007 Feb;100(3):802-9
references.pmid: 17156133
references.citation: Biochim Biophys Acta. 2010 Apr;1802(4):373-88
references.pmid: 20060898
references.citation: Neurology. 2009 Jul 28;73(4):287-93
references.pmid: 19636048
references.citation: J Neurosci. 2001 Jan 15;21(2):372-81
references.pmid: 11160418
references.citation: Neuroimage. 2010 Jun;51(2):586-98
references.pmid: 20206704
references.citation: Int Psychogeriatr. 2009 Aug;21(4):672-87
references.pmid: 19470201
references.citation: Alzheimer Dis Assoc Disord. 2007 Oct-Dec;21(4):292-9
references.pmid: 18090435
references.citation: Alzheimers Dement. 2009 Sep;5(5):388-97
references.pmid: 19751918